Genetic Predisposition to Advanced Glycation End Products Toxicity Is Related to Prognosis of Chronic Hemodialysis Patients

被引:17
|
作者
Kalousova, Marta [1 ,2 ]
Jachymova, Marie [1 ,2 ]
Germanova, Alexandra [1 ,2 ]
Kubena, Ales Antonin [4 ]
Tesar, Vladimir [3 ]
Zima, Tomas [1 ,2 ]
机构
[1] Charles Univ Prague, Fac Med 1, Inst Clin Biochem, CZ-12111 Prague 2, Czech Republic
[2] Charles Univ Prague, Fac Med 1, Diagnost Lab, CZ-12111 Prague, Czech Republic
[3] Charles Univ Prague, Fac Med 1, Dept Nephrol, CZ-12111 Prague 2, Czech Republic
[4] Charles Univ Prague, Fac Pharm Hradec Kralove, CZ-12111 Prague 2, Czech Republic
来源
KIDNEY & BLOOD PRESSURE RESEARCH | 2010年 / 33卷 / 01期
关键词
Advanced glycation end products; Cardiovascular mortality; Glyoxalase; Hemodialysis; Polymorphisms; Receptor for advanced glycation end products; Soluble receptor for advanced glycation end products; CORONARY-ARTERY-DISEASE; TYPE-2; DIABETES-MELLITUS; STAGE RENAL-DISEASE; RAGE GENE; GLYOXALASE-I; CARDIOVASCULAR-DISEASE; INFLAMMATORY RESPONSE; THE-374A ALLELE; RECEPTOR; POLYMORPHISM;
D O I
10.1159/000285845
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Background: Advanced glycation end products (AGEs) belong to uremic toxins and some pathological effects of AGEs are linked to RAGE (receptor for AGEs). Their precursors are detoxified by the glyoxalase (GLO) system. The A419C (E111A) polymorphism of the GLO I gene is associated with vascular disease in hemodialysis (HD) patients and some RAGE gene polymorphisms are implicated in various pathological states. Aim: To study the relationship of A419C GLO I and four RAGE polymorphisms (-429T/C, -374T/A, 2184A/G and Gly82Ser) in the prognosis of HD patients. Methods: The group studied consisted of 214 chronic HD patients prospectively followed up for 43 months. 100 patients died, 48 due to cardiovascular causes. Results: The Kaplan-Meier analysis showed a higher mortality rate in patient-mutated homozygotes for RAGE -429CC, RAGE 2184GG and GLO I419CC. A higher hazard risk was confirmed by the Cox proportional hazards model when wild-type homozygotes were taken as reference: RAGE -429CC 2.28 (95% CI 1.04-4.99), RAGE 2184GG 3.16 (95% CI 1.44-6.93), and GLO I419CC 1.75 (95% CI 1.08-2.86). Both RAGE polymorphisms were also associated with cardiovascular mortality: RAGE -429CC 3.54 (95% CI 1.37-9.14) and RAGE 2184GG 5.04 (95% CI 1.93-13.11). Conclusion: In summary, our study shows for the first time a link between RAGE and GLO polymorphisms in the prognosis of HD patients. Copyright (C) 2010 S. Karger AG, Basel
引用
收藏
页码:30 / 36
页数:7
相关论文
共 50 条
  • [1] Advanced glycation end products and mortality in hemodialysis patients
    Schwedler, SB
    Metzger, T
    Schinzel, R
    Wanner, C
    KIDNEY INTERNATIONAL, 2002, 62 (01) : 301 - 310
  • [2] Hemodialysis techniques and advanced glycation end products
    Tessitore, N
    Lapolla, A
    Aricó, CN
    Gammaro, L
    Bernich, P
    Fedele, D
    ADVANCED GLYCATION END PRODUCTS IN NEPHROLOGY, 2001, 131 : 33 - 39
  • [3] Receptor for advanced glycation end products - soluble form and gene polymorphisms in chronic hemodialysis patients
    Kalousova, Marta
    Jachymova, Marie
    Mestek, Oto
    Hodkova, Magdalena
    Kazderova, Marketa
    Tesar, Vladimir
    Zima, Tomas
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 : 183 - 183
  • [4] Plasma Catestatin Levels and Advanced Glycation End Products in Patients on Hemodialysis
    Luketin, Mirko
    Mizdrak, Maja
    Boric-Skaro, Dijana
    Martinovic, Dinko
    Tokic, Daria
    Vilovic, Marino
    Supe-Domic, Daniela
    Ticinovic Kurir, Tina
    Bozic, Josko
    BIOMOLECULES, 2021, 11 (03) : 1 - 15
  • [5] Toxicity of advanced glycation end products (Review)
    Kuzan, Aleksandra
    BIOMEDICAL REPORTS, 2021, 14 (05)
  • [6] Cardiac troponin T and advanced glycation end-products in hemodialysis patients
    Taki, Kentaro
    Tsuruta, Yoshinari
    Niwa, Toshimitsu
    AMERICAN JOURNAL OF NEPHROLOGY, 2008, 28 (05) : 701 - 706
  • [7] Serum advanced glycation end products are not associated with muscle strength in hemodialysis patients
    Silva, Debora M.
    Queiroz, Nayara P.
    Freitas, Ana Tereza V. S.
    Passarelli, Marisa
    Corgosinho, Flavia Campos
    Peixoto, Maria do Rosario G.
    EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2019, 73 (04) : 617 - 623
  • [8] Serum advanced glycation end products are not associated with muscle strength in hemodialysis patients
    Debora M. Silva
    Nayara P. Queiroz
    Ana Tereza V. S. Freitas
    Marisa Passarelli
    Flávia Campos Corgosinho¹
    Maria do Rosário G. Peixoto
    European Journal of Clinical Nutrition, 2019, 73 : 617 - 623
  • [9] Uremic Toxicity of Advanced Glycation End Products in CKD
    Stinghen, Andrea E. M.
    Massy, Ziad A.
    Vlassara, Helen
    Striker, Gary E.
    Boullier, Agnes
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2016, 27 (02): : 354 - 370
  • [10] Receptor for advanced glycation end products (RAGE) -: Soluble form (sRAGE) and gene polymorphisms in chronic hemodialysis patients
    Kalousova, M.
    Jáchymová, M.
    Mestek, O.
    Hodková, M.
    Kazderová, M.
    Tesaï, V.
    Zima, T.
    FREE RADICAL RESEARCH, 2006, 40 : S112 - S112